Mature CD83+ dendritic cells infected with recombinant gp100 vaccinia virus stimulate potent antimelanoma T cells

Annals of Surgical Oncology

Volumn 9, Issue 4, 2002, Pages 411-418

  Prabakaran, Indira ^a   Menon, Chandrakala ^a   Xu, Shuwen ^a   Gómez Yafal, Alicia ^b   Czerniecki, Brian J ^a   Fraker, Douglas L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Therion Biologics Corporation   (United States)

Author keywords

CD8+; Dendritic cells; gp100; Melanoma; Tumor associated antigen; Vaccinia virus

Indexed keywords

CANCER VACCINE; CD83 ANTIGEN; EPITOPE; PROTEIN RV LACZ; RECOMBINANT GLYCOPROTEIN GP 100; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CALCIUM SIGNALING; CELL MATURATION; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC CODE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LYMPHOCYTE CULTURE; MELANOMA CELL; MIXED TUMOR; NONHUMAN; PROTEIN EXPRESSION; T LYMPHOCYTE; TARGET CELL; TRANSGENE; VACCINIA VIRUS; VIRAL GENE THERAPY;

ANTIGEN PRESENTATION; ANTIGENS, CD; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; IMMUNOGLOBULINS; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; TUMOR CELLS, CULTURED; VACCINIA VIRUS;

EID: 0036256220     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/aso.2002.9.4.411     Document Type: Article

References (41)

1. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution
2. The dendritic cell system and its role in immunogenicity
3. Tolerance, danger and the extended family
4. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo
5. Tumor antigen presentation by murine epidermal cells
6. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes
7. Regression of human metastatic renal cell carcinoma after vaccination with cell-dendritic cell hybrids
8. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce anti-tumor immunity against central nervous system tumors
9. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
10. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
11. Immunological and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
12. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
13. Dendritic cell-based immunotherapy of prostate cancer
14. A phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
15. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects
16. + melanoma patients by mature monocyte-derived dendritic cells
17. + hematopoietic progenitor cells
18. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells
19. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation
20. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
21. Calcium ionophore-treated peripheral blood monocyte and dendritic cells rapidly display characteristics of activated dendritic cells
22. Granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-12 synergize with calcium ionophore to enhance dendritic cell function
23. Calcium signaling induces the acquisition of dendritic cell characteristics in CML myeloid progenitor cells
24. Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity
25. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3
26. + T cells
27. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens
28. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells
29. Murine dendritic cells transfected with human gp100 elicit both antigen-specific CD8 and CD4 T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity
30. + T lymphocytes
31. Induction of anti-tumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens
32. Generation and analysis of vaccinia virus recombinants
33. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes
34. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids
35. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
36. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1
37. The biochemistry and cell biology of antigen processing and presentation
38. + dendritic cells that induce Th2 cell development
39. Adenovirus type 5 vectors induce dendritic cell differentiation in human CD14(+) monocytes cultured under serum-free conditions
40. + T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection
41. + monocyte-derived dendritic cells and the implications for cancer vaccines